"Direct to consumer microbiome analyzing market to exhibit dynamic growth during the forecast period"
The global direct to consumer microbiome analyzing market is growing efficiently, expected to grow at a CAGR of 11.8%. Globally, growing prevalence of chronic diseases along with gut infections has significantly increased the revenue of microbiome testing kits. New product launches along with raised funding for genome testing, and promising pipeline microbiome analyzing products in the DNA testing industry are factors driving the overall growth of direct to consumer microbiome analyzing market globally.
"Gut microbiome test kits segment is expected to register higher growth by the end of 2033"
Advancement in diagnostic testing along with sequencing-based clinical microbiome analyzing will enhance future growth. Direct to consumer DNA testing is expanding significantly, has the capability to detect specific infections, lifestyle diseases, and gut conditions including irritable bowel syndrome and inflammatory bowel disease. For e.g. SmartGut (uBiome, Inc.), it is the world’s first sequencing-based clinical microbiome test. The global giants are investing for further R&D and are encouraging the commercialization of these sample kits in partnerships with smaller organizations to meet the active demand in future.
"Expansion of services at home for gut microbiome testing to witness a significant CAGR"
Increasing popularity of DNA testing kits along with services provided at home on a global level are notable factors expected for the growth of the market. Citizen scientists around the world are learning about their microbiomes. These kits are useful for various disease indications and applications including diarrhea, irritable bowel syndrome, inflammatory bowel disease, Crohn’s disease and ulcerative colitis, obesity, type 2 diabetes, chronic kidney disease, cardiovascular disease, and many others. The genetics industry is now familiar with the consumer interest in microbiome testing as an opportunity, and a number of top commercial laboratories are marketing these test kits directly on a global level, mainly in the U.S. and Europe markets.
"Increasing population, new FDA approval and the presence of top players hold the U.S. in dominant position"
In 2024, North America generated the maximum revenue share in the direct-to-consumer microbiome analyzing market due to an increase in the expansion of test kits along with raising awareness about new technology with improved outcomes at low cost. Rising home care services along with enhanced reimbursement structure will drive growth in the near future. For e.g. In Dec 2019, direct-to-consumer DNA and microbiome test were launched in Europe. Atlas Biomed expanded its consumer-oriented DNA and gut microbiome tests with combined analysis on the corporation’s health program. Nevertheless, huge pipeline products, less awareness, accuracy along with data security and FDA regulations are factors restraining the overall growth of the market.
"Increased research and development with strong product pipelines in the developed regions"
Major players in the direct-to-consumer microbiome analyzing market are uBiome, Inc., Viome, Inc., Atlas Biomed, and others. Major top organizations and DNA testing and research centers are developing smart technologies with integrated systems. Acquisitions, partnerships, and enhanced R&D will improvise the expansion of direct-to-consumer microbiome analyzing market in developing nations in near future.
Historical & Forecast Period
This study report represents analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Direct to Consumer Microbiome Analyzing market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
ATTRIBUTE | DETAILS |
---|---|
Research Period | 2023-2033 |
Base Year | 2024 |
Forecast Period | 2025-2033 |
Historical Year | 2023 |
Unit | USD Million |
Segmentation | |
Product
| |
Application
| |
Region Segment (2023-2033; US$ Million)
|
Key questions answered in this report